Cipher Pharmaceuticals (TSE:CPH) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) posted its quarterly earnings data on Thursday. The company reported C$0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.03 by C($0.02), reports. The firm had revenue of C$14.15 million for the quarter, compared to analyst estimates of C$13.37 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%.

Cipher Pharmaceuticals Stock Down 10.7 %

Shares of Cipher Pharmaceuticals stock opened at C$13.88 on Friday. Cipher Pharmaceuticals has a 12 month low of C$4.40 and a 12 month high of C$19.69. The business has a fifty day simple moving average of C$16.19 and a 200 day simple moving average of C$12.24. The company has a quick ratio of 2.67, a current ratio of 11.18 and a debt-to-equity ratio of 0.33. The stock has a market cap of C$355.19 million, a PE ratio of 11.10 and a beta of 1.20.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on CPH shares. Stifel Canada upgraded Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th. Stifel Nicolaus raised their target price on shares of Cipher Pharmaceuticals from C$17.00 to C$19.00 in a research note on Thursday, October 24th. Finally, Leede Financial cut shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 13th.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.